Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Non-Current Assets (2016 - 2025)

Rein Therapeutics filings provide 10 years of Other Non-Current Assets readings, the most recent being $2000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of $2000.0, changed 0.0% over the prior year.
  • Other Non-Current Assets hit $2000.0 in Q4 2025 for Rein Therapeutics, roughly flat from $2000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $766000.0 in Q1 2025, with the low at $2000.0 in Q2 2024.
  • Median Other Non-Current Assets over the past 5 years was $24000.0 (2021), compared with a mean of $55750.0.
  • The sharpest move saw Other Non-Current Assets tumbled 96.3% in 2021, then soared 2964.0% in 2025.
  • Year by year, Other Non-Current Assets stood at $24000.0 in 2021, then changed by 0.0% to $24000.0 in 2022, then rose by 4.17% to $25000.0 in 2023, then plummeted by 92.0% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $2000.0, $2000.0, and $2000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.